Gynecological Cancer

SS 24 - GYN 1

169 - Preliminary Results of Nimotuzumab Plus Concurrent IMRT and Chemotherapy on Cervical Cancer

Tuesday, October 23
1:30 PM - 1:40 PM
Location: Room 007 A/B

Preliminary Results of Nimotuzumab Plus Concurrent IMRT and Chemotherapy on Cervical Cancer
A. Qu, P. Wang, M. Zhang, P. Jiang, X. Deng, and J. Wang; Peking University Third Hospital, Beijing, China

Purpose/Objective(s): To evaluate the safety and efficacy of nimotuzumab plus concurrent IMRT and chemotherapy of unresectable cervical cancer.

Materials/Methods: From December 2013 to February 2017, 34 patients with cervical cancer on stage (FIGO) IB2-IVB were received concurrent chemoradiation plus nimotuzumab. The prescription dose of radiation was 50.4 Gy/28f on pelvic field with or with not extended field radiation. An additional 30-36 Gy to Point A were delivered with high-dose-rate techniques. Cisplatin of 40 mg/m2 and nimotuzumab of 200mg were infused intravenously once weekly during RT for 6 weeks. The main outcome measure was toxicity evaluated by CTCAE 4.0. Secondary outcome measure was short-term outcome evaluated by RESIST1.1.

Results: The median of followed up time was 23.4 months (8.3-45.5 months). Almost all patients were local advantaged cancer except 2 patients with distant metastases. All patients received external radiation therapy. 2 patients were not treated with brachytherapy. 6 patients failed to finish radiation therapy within 56 days. All of 34 patients received concurrent treatment with nimotuzumab for 6 times. 2 patients refused chemotherapy. There was no life-threatening toxicity. Grade 1/2 of nausea, vomiting and diarrhea were 70.6% (24/34), 32.4% (11/34) and 52.9%(18/34), respectively. Grade 3 of leucopenia, granulopenia, thrombocytopenia and anemia were 52.9% (18/34), 17.6% (6/34), 14.7% (5/34), 11.8% (4/34), respectively. Grade 3 of nausea and vomiting were 8.8% (3/34) and 2.9% (1/34), respectively. No grade 3 of anorectal inflammation. Rectovaginal fistula was observed in one case 6 months after radiation therapy, and operation was performed. Surgical treatment of intestinal obstruction was performed in one case. 2 cases got vaginal stenosis. The objective response rate was 100%. Complete response was achieved in 29 cases (85.3%) and partial response in 5 cases (14.7%).

Conclusion: Nimotuzumab plus concurrent IMRT and chemotherapy may represent an effective and well-tolerated treatment in patients with unresectable cervical cancer.

Author Disclosure: A. Qu: None. P. Wang: None. M. Zhang: None.

Ang Qu, MD

Disclosure:
No relationships to disclose.

Biography:
Ang Qu, M.D, attending doctor, Radiation Oncology Department, Peking University Third Hospital. Graduated from Peking University Health Science Center. The specialty is radiotherapy on gynecological cancer, including external beam radiation, HDR intracavitary and interstitial brachytherapy, and LDR radioactive seeds permanent implantation. Developing 3D-printing template assisted HDR interstitial implantation on recurrent gynecological cancer.

Presentation(s):

Send Email for Ang Qu


Assets

169 - Preliminary Results of Nimotuzumab Plus Concurrent IMRT and Chemotherapy on Cervical Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Preliminary Results of Nimotuzumab Plus Concurrent IMRT and Chemotherapy on Cervical Cancer